Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · see citing works

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works

Hearing loss and cognitive decline in older adults

Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017 · see citing works

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · see citing works

Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis

Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · see citing works

Down's syndrome

Roizen, N., & Patterson, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12987-x · Cited by 1,333 · see citing works

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · see citing works

Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers

Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,180 · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease

Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa‐Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,093 · see citing works

Cerebral amyloid angiopathy. A critical review.

Vinters, H. V. (1987) · Stroke · doi:10.1161/01.str.18.2.311 · Cited by 1,070 · see citing works

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works

The cholinergic system in aging and neuronal degeneration

Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047 · see citing works

Intraneuronal Aβ42 Accumulation in Human Brain

Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · see citing works

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 827 · see citing works

Untitled work

(1959) · PubMed · Cited by 820 · see citing works

Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

Cataldo, A., Peterhoff, C., Troncoso, J., Gómez-Isla, T., Hyman, B., & Nixon, R. (2000) · American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 789 · see citing works

The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease

Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., & Ashe, K. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01858.2002 · Cited by 714 · see citing works

Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease

Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 652 · see citing works

Mechanisms of tau-induced neurodegeneration

Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628 · see citing works

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E

Barger, S. W., & Harmon, A. D. (1997) · Nature · doi:10.1038/42257 · Cited by 622 · see citing works

Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains

Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · see citing works

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease

Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603 · see citing works

Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques

Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · see citing works

Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation

Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · see citing works

A Prospective Study of Alzheimer Disease in Down Syndrome

Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561 · see citing works

Clearing the brain's amyloid cobwebs

Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541 · see citing works

Disease‐specific patterns of locus coeruleus cell loss

German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512 · see citing works

Regulation of APP cleavage by α‐, β‐ and γ‐secretases

Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 509 · see citing works

Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

Walsh, D. M., Klyubin, I. V., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507 · see citing works

The four ages of Down syndrome.

Bittles, A., Bower, C., Hussain, R., & Glasson, E. (2007) · European Journal of Public Health · doi:10.1093/eurpub/ckl103 · Cited by 505 · see citing works

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484 · see citing works

The changing survival profile of people with Down's syndrome: implications for genetic counselling

Glasson, E. J., Sullivan, S. G., Hussain, R., Petterson, B. A., Montgomery, P. D., & Bittles, A. H. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.620506.x · Cited by 477 · see citing works

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471 · see citing works

Assessing Activation States in Microglia

Colton, C. A., & Wilcock, D. M. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012053 · Cited by 421 · see citing works

Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome

Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., & Yankner, B. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00604-9 · Cited by 387 · see citing works

Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome

Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N., & Ihara, Y. (1995) · Annals of Neurology · doi:10.1002/ana.410370305 · Cited by 380 · see citing works

Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome

Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363 · see citing works

Pathology and pathogenesis of vascular cognitive impairment—a critical update

Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353 · see citing works

Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice

Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., & Bayer, T. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01876-6 · Cited by 336 · see citing works

Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome

Teller, J. K., Russo, C., DeBusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D. M. A., Tabaton, M., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-93 · Cited by 326 · see citing works

Neuronal Oxidative Stress Precedes Amyloid-β Deposition in Down Syndrome

Nunomura, A., Perry, G. L., Pappolla, M. A., Friedland, R. P., Hirai, K., Chiba, S., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.11.1011 · Cited by 322 · see citing works

Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition

Dam, D. V., D’Hooge, R., Staufenbiel, M., Ginneken, C. J. V., Meir, F. V., & Deyn, P. P. D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02444.x · Cited by 297 · see citing works

Down syndrome and Alzheimer's disease: common pathways, common goals

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290 · see citing works

Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease

Reed, B. R., Mungas, D. M., Kramer, J. H., Ellis, W., Vinters, H. V., Zarow, C., Jagust, W. J., & Chui, H. C. (2007) · Brain · doi:10.1093/brain/awl385 · Cited by 282 · see citing works

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281 · see citing works

Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain

Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., & Kawashima, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12970-0 · Cited by 270 · see citing works

Atypical aging in down syndrome

Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 262 · see citing works

β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 259 · see citing works

Intraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles

Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255 · see citing works

Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques.

Iwatsubo, T., Saido, T. C., Mann, D. M. A., Lee, V. M.-Y., & Trojanowski, J. Q. (1996) · Europe PMC (PubMed Central) · Cited by 248 · see citing works

Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome

Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248 · see citing works

Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome

Hof, P. R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280065020 · Cited by 234 · see citing works

Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., & Glabe, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7437 · Cited by 233 · see citing works

Intracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease

Glabe, C. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:137 · Cited by 222 · see citing works

Down's syndrome: an atheroma-free model?

Murdoch, J. C., Rodger, J. C., Rao, S. S., Fletcher, C., & Dunnigan, M. G. (1977) · BMJ · doi:10.1136/bmj.2.6081.226 · Cited by 221 · see citing works

Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis

Leverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214 · see citing works

Adult-derived neural precursors transplanted into multiple regions in the adult brain

Herrera, D. G., García‐Verdugo, J. M., & Álvarez-Buylla, A. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6 · Cited by 204 · see citing works

Abnormalities of the nucleus basalis in Down's syndrome

Casanova, M. F., Walker, L. C., Whitehouse, P. J., & Price, D. L. (1985) · Annals of Neurology · doi:10.1002/ana.410180306 · Cited by 202 · see citing works

The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration

Melchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202 · see citing works

White Matter Hyperintensities and Cerebral Amyloidosis: Necessary and Sufficient for Clinical Expression of Alzheimer Disease?

Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1321 · Cited by 192 · see citing works

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome

Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190 · see citing works

Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease

Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., Pooter, T. D., van Duijn, C. M., Deyn, P. P. D., & Broeckhoven, C. V. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 187 · see citing works

Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease

Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187 · see citing works

Adaptive Downregulation of Mitochondrial Function in Down Syndrome

Helguera, P. R., Seiglie, J., Rodríguez, J. A., Hanna, M., Helguera, G. F., & Busciglio, J. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.005 · Cited by 179 · see citing works

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions

Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M., & Demuth, H. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00300-x · Cited by 172 · see citing works

White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions

Gold, B. T., Johnson, N. F., Powell, D. K., & Smith, C. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.009 · Cited by 170 · see citing works

Systemic Mitochondrial Dysfunction and the Etiology of Alzheimer's Disease and Down Syndrome Dementia

Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E. W., Lott, I. T., Head, E., Cotman, C. W., & Wallace, D. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100351 · Cited by 158 · see citing works

ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site

Hussain, I., Powell, D. J., Howlett, D. R., Chapman, G. A., Gilmour, L., Murdock, P. R., Tew, D. G., Meek, T. D., Chapman, C. G., Schneider, K., et al. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0884 · Cited by 156 · see citing works

Vascular burden and Alzheimer disease pathologic progression

Lo, R. Y., Jagust, W. J., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1b9d · Cited by 156 · see citing works

Precocious aging and dementia in patients with Down's syndrome.

Wisniewski, K. E., Howe, J., Williams, D. G., & Wisniewski, H. M. (1978) · PubMed · Cited by 153 · see citing works

Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome

Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 148 · see citing works

Neuropathological Changes in Down's Syndrome Hippocampal Formation

Hyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 147 · see citing works

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain

Nistor, M., Don, M., Parekh, M., Sarsoza, F. M., Goodus, M. T., López, G., Kawas, C. H., Leverenz, J. B., Doran, E. W., Lott, I. T., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.023 · Cited by 135 · see citing works

The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system

Mann, D. M. A. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90100-8 · Cited by 135 · see citing works

The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid

Lalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wı́sniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 134 · see citing works

Amyloid-β Toxicity and Tau Hyperphosphorylation are Linked Via RCAN1 in Alzheimer's Disease

Lloret, A., Badía, M.-C., Giraldo, E., Ermak, G., Alonso, M.-D., Pallardó, F. V., Davies, K. J. A., & Viña, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110890 · Cited by 133 · see citing works

Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain

Domenico, F. D., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schininà, M. E., Mancuso, C., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.013 · Cited by 133 · see citing works

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 132 · see citing works

Down syndrome and beta-amyloid deposition

Head, E., & Lott, I. T. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200404000-00003 · Cited by 125 · see citing works

Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome

Cenini, G., Dowling, A. L. S., Beckett, T. L., Barone, E., Mancuso, C., Murphy, M. P., LeVine, H., Lott, I. T., Schmitt, F. A., Butterfield, D. A., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.001 · Cited by 122 · see citing works

Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991.

Strauss, D., & Eyman, R. K. (1996) · PubMed · Cited by 121 · see citing works

Early Glycoxidation Damage in Brains from Down's Syndrome

Odetti, P. R., Angelini, G., Dapino, D., Zaccheo, D., Garibaldi, S., Dagna-Bricarelli, F., Piombo, G., Perry, G. L., Smith, M. A., Traverso, N., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8186 · Cited by 116 · see citing works

Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain

Butterfield, D. A., Domenico, F. D., Swomley, A. M., Head, E., & Marzia Perluigi, A. (2014) · Biochemical Journal · doi:10.1042/bj20140772 · Cited by 111 · see citing works

Down's syndrome and atherosclerosis

Ylä‐Herttuala, S., Luoma, J. S., Nikkari, T., & Kivimäki, T. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90110-x · Cited by 110 · see citing works

Intracellular Accumulation of Insoluble, Newly Synthesized Aβn-42 in Amyloid Precursor Protein-transfected Cells That Have Been Treated with Aβ1–42

Yang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A., & Glabe, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20650 · Cited by 108 · see citing works

Increased plasma amyloid β protein 1–42 levels in Down syndrome

Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108 · see citing works

Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease

Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104 · see citing works

Complement Association with Neurons and β-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome

Head, E., Azizeh, B. Y., Lott, I. T., Tenner, A. J., Cotman, C. W., & Cribbs, D. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0380 · Cited by 103 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease

Domenico, F. D., Pupo, G., Tramutola, A., Giorgi, A., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., & Marzia Perluigi, A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.027 · Cited by 98 · see citing works

RCAN1‐1L is overexpressed in neurons of Alzheimer's disease patients

Harris, C. D., Ermak, G., & Davies, K. J. A. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05717.x · Cited by 97 · see citing works

Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease

Liu, K., Solano, I., Mann, D. M. A., Lemere, C. A., Mercken, M. H., Trojanowski, J. Q., & Lee, V. M. ‐. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0077-5 · Cited by 94 · see citing works

Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome

Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N., & Tamaoka, A. (1997) · Annals of Neurology · doi:10.1002/ana.410410220 · Cited by 92 · see citing works

Protein expression of BACE1, BACE2 and APP in Down syndrome brains

Cheon, M. S., Dierssen, M., Kim, S. H., & Lübec, G. (2007) · Amino Acids · doi:10.1007/s00726-007-0618-9 · Cited by 92 · see citing works

Possible Compensatory Events in Adult Down Syndrome Brain Prior to the Development of Alzheimer Disease Neuropathology: Targets for Nonpharmacological Intervention

Head, E., Lott, I. T., Patterson, D. W., Doran, E. W., & Haier, R. J. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11110 · Cited by 89 · see citing works

Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome

Coppus, A. M. W., Schuur, M., Vergeer, J., Janssens, A. C. J. W., Oostra, B. A., Verbeek, M. M., & van Duijn, C. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.007 · Cited by 88 · see citing works

Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?

Struble, R. G., Ala, T., Patrylo, P. R., Brewer, G. J., & Yan, X. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100846 · Cited by 84 · see citing works

Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

Schupf, N., Zigman, W. B., Tang, M. X., Pang, D. I., Mayeux, R. P., Mehta, P. D., & Silverman, W. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 78 · see citing works

The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age

Fonseca, M. I., Head, E., Velázquez, P., Cotman, C. W., & Tenner, A. J. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7058 · Cited by 75 · see citing works

Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome

Head, E., Garzon-Rodriguez, W., Johnson, J. K., Lott, I. T., Cotman, C. W., & Glabe, C. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0431 · Cited by 75 · see citing works

Plasma Amyloid-β as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome

Head, E., Doran, E. W., Nistor, M., HILL, M., Schmitt, F. A., Haier, R. J., & Lott, I. T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101335 · Cited by 73 · see citing works

Cerebral microbleeds are related to loss of white matter structural integrity

Akoudad, S., de Groot, M., Koudstaal, P. J., van der Lugt, A., Niessen, W. J., Albert Hofman, D., Ikram, M. A., & Vernooij, M. W. (2013) · Neurology · doi:10.1212/01.wnl.0000436609.20587.65 · Cited by 73 · see citing works

Microglial pathology in Down syndrome

Xue, Q., & Streit, W. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0864-5 · Cited by 72 · see citing works

Comparison of Intima-Media Thickness of the Carotid Artery and Cardiovascular Disease Risk Factors in Adults With Versus Without the Down Syndrome

Draheim, C. C., Geijer, J. R., & Dengel, D. R. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.079 · Cited by 71 · see citing works

Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia

Haier, R. J., Alkire, M. T., White, N. S., Uncapher, M. R., Head, E., Lott, I. T., & Cotman, C. W. (2003) · Neurology · doi:10.1212/01.wnl.0000098935.36984.25 · Cited by 71 · see citing works

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69 · see citing works

Low Blood Pressure in Down's Syndrome

Rd, M., McGrath, A., Davidson, G., Brown, J. J., Murray, G. D., & Lever, A. F. (1996) · Hypertension · doi:10.1161/01.hyp.28.4.569 · Cited by 68 · see citing works

Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease

Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64 · see citing works

Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 63 · see citing works

BACE2 Expression Increases in Human Neurodegenerative Disease

Holler, C. J., Webb, R. L., Laux, A. L., Beckett, T. L., Niedowicz, D. M., Ahmed, R. R., Liu, Y., Simmons, C. R., Dowling, A. L. S., Spinelli, A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.034 · Cited by 63 · see citing works

Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age

Mann, D. M. A., Yates, P. O., Marcyniuk, B., & Ravindra, C. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90223-1 · Cited by 61 · see citing works

Lipids and lipoproteins in persons with Down's syndrome

Pueschel, S. M., Craig, W. Y., & Haddow, J. E. (1992) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.1992.tb00535.x · Cited by 60 · see citing works

Molecular Dating of Senile Plaques in the Brains of Individuals with Down Syndrome and in Aged Dogs

Azizeh, B. Y., Head, E., Ibrahim, M. A., Torp, R., Tenner, A. J., Kim, R. C., Lott, I. T., & Cotman, C. W. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7359 · Cited by 58 · see citing works

Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43)

Mann, D. M. A., & Iwatsubo, T. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0017 · Cited by 52 · see citing works

Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid

Portelius, E., Soininen, H. S., Andréasson, U., Zetterberg, H., Persson, R., Karlsson, G., Blennow, K., Herukka, S., & Mattsson, N. (2014) · Neurodegenerative Diseases · doi:10.1159/000358800 · Cited by 50 · see citing works

Tau and apo E in CSF

Molina, L., Touchon, J., Herpé, M., Lefranc, D., Duplan, L., Cristol, J., Sabatier, R., Vermersch, P., Pau, B., & Mourton-Gilles, C. (1999) · Neuroreport · doi:10.1097/00001756-199911260-00005 · Cited by 49 · see citing works

BACE-2 is overexpressed in Down’s syndrome

Barbiero, L., Benussi, L., Ghidoni, R., Alberici, A., Russo, C., Schettini, G., Pagano, S., Parati, E. A., Mazzoli, F., Nicosia, F. M., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00049-9 · Cited by 49 · see citing works

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues, A., Coelho, Gonçalves, W. L. S., Gouvêa, Vasconcellos, Cunha, & Abreu (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s21273 · Cited by 49 · see citing works

Plasma amyloid β protein 1–42 levels are increased in old Down Syndrome but not in young Down Syndrome

Mehta, P. D., Mehta, S. P., Fedor, B. L., Patrick, B. A., Emmerling, M. R., & Dalton, A. J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00275-1 · Cited by 48 · see citing works

Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome

Hirayama, A., Horikoshi, Y., Maeda, M., Ito, M., & Takashima, S. (2003) · Brain and Development · doi:10.1016/s0387-7604(02)00209-7 · Cited by 45 · see citing works

DOES DOWN SYNDROME SUPPORT HOMOCYSTEINE THEORY OF ARTERIOSCLEROSIS?

Brattström, L. E., Englund, E. M., & Brun, A. E. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91772-7 · Cited by 45 · see citing works

Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome

Motonaga, K., Itoh, M., Becker, L. E., Goto, Y.-I., & Takashima, S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00287-2 · Cited by 45 · see citing works

Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10) ?

Tiano, L., & Busciglio, J. (2011) · Biofactors · doi:10.1002/biof.184 · Cited by 43 · see citing works

Altered Composition of Polyunsaturated Fatty Acyl Groups in Phosphoglycerides of Down's Syndrome Fetal Brain

Brooksbank, B. W. L., Martínez, M., & Balázs, R. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb12896.x · Cited by 41 · see citing works

Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy

Donahue, J. E., Khurana, J. S., & Adelman, L. S. (1998) · Acta Neuropathologica · doi:10.1007/s004010050789 · Cited by 40 · see citing works

Plasma β‐amyloid and duration of Alzheimer's disease in adults with Down syndrome

Prasher, V. P., Sajith, S. G., Mehta, P. D., Zigman, W. B., & Schupf, N. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2321 · Cited by 40 · see citing works

CSF tau and Aβ42 levels in patients with Down’s syndrome

Tapiola, T., Soininen, H. S., & Pirttilä, T. (2001) · Neurology · doi:10.1212/wnl.56.7.979 · Cited by 39 · see citing works

Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology

Sadowski, M. J., Wı́sniewski, H. M., Tarnawski, M. J., Kozlowski, P. B., Lach, B., & Węgiel, J. (1999) · Acta Neuropathologica · doi:10.1007/s004010050968 · Cited by 38 · see citing works

Increase in β-Amyloid Levels in Cerebrospinal Fluid of Children with Down Syndrome

Englund, H., Annerén, G., Gustafsson, J., Oxelgren, U. W., Wiltfang, J., Lannfelt, L., Blennow, K., & Höglund, K. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000109215 · Cited by 38 · see citing works

Cerebral amyloid angiopathy in Down's syndrome.

Belza, M. G., & Urich, H. (1986) · PubMed · Cited by 37 · see citing works

Parallel Compensatory and Pathological Events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome

Head, E., Lott, I. T., Hof, P. R., Bouras, C., Su, J., Kim, R., Haier, R. J., & Cotman, C. W. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.9.917 · Cited by 36 · see citing works

A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors

McCarron, M. O., Nicoll, J. A. R., & Graham, D. I. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.3.405 · Cited by 34 · see citing works

Amyloid β concentrations in older people with Down syndrome and dementia

Jones, E. L., Hanney, M., Francis, P. T., & Ballard, C. G. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.12.030 · Cited by 33 · see citing works

Plasma levels of amyloid ? 40 and 42 are independent from ApoE genotype and mental retardation in down syndrome

Cavani, S., Tamaoka, A., Moretti, A., Marinelli, L., Angelini, G., Stefano, S. D., Piombo, G., Cazzulo, V., Matsuno, S., Shoji, S., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001127)95:3 · Cited by 33 · see citing works

Accumulation of Insoluble Amyloid-β in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities

Miners, J. S., Morris, S., Love, S., & Kehoe, P. G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101395 · Cited by 30 · see citing works

The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome

Matsuoka, Y., Andrews, H., Becker, A. G., Gray, A. J., Mehta, P. D., Sano, M. C., Dalton, A. J., & Aisen, P. S. S. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181aba61e · Cited by 29 · see citing works

Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability

Jansen, J., Rozeboom, W., Penning, C., & Evenhuis, H. M. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01567.x · Cited by 29 · see citing works

Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome

Portelius, E., Hölttä, M., Soininen, H. S., Bjerke, M., Zetterberg, H., Westerlund, A., Herukka, S., Blennow, K., & Mattsson, N. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8302-1 · Cited by 28 · see citing works

Ubiquitin-immunoreactive Dystrophic Neurites in Downʼs Syndrome Brains

Mattiace, L. A., Kress, Y., Davies, P., Ksiȩżak-Reding, H., Yen, S. H., & Dickson, D. W. (1991) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199109000-00003 · Cited by 28 · see citing works

β -Secretases, Alzheimer’s Disease, and Down Syndrome

Webb, R. L., & Murphy, M. P. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/362839 · Cited by 24 · see citing works

β-Amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome

Head, E., Lott, I. T., Cribbs, D. H., Cotman, C. W., & Rohn, T. T. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00705-x · Cited by 23 · see citing works

Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report.

Mendel, T. A., Bertrand, E., Szpak, G. M., Stępień, T., & Wierzba‐Bobrowicz, T. (2010) · PubMed · Cited by 23 · see citing works

Variability of .BETA.-Amyloid Protein Deposited Lesions in Down's Syndrome Brains.

Ikeda, S.-I., Tokuda, T., Yanagisawa, N., Kametani, F., Ohshima, T., & Allsop, D. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.174.189 · Cited by 22 · see citing works

Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome

Naito, K., Sekijima, Y., & Ikeda, S. (2008) · Amyloid · doi:10.1080/13506120802524981 · Cited by 19 · see citing works

Plaques and Tangles: Searching for Primary Events in a Forest of Data

Cummings, B. J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00049-3 · Cited by 16 · see citing works

Lectin-histochemical detection of degenerative glycoconjugate deposits in human brain

Nishimura, A., Sawada, S., Ushiyama, I., Yamamoto, Y., Nakagawa, T., Tanegashima, A., & Nishi, K. (2000) · Forensic Science International · doi:10.1016/s0379-0738(00)00228-0 · Cited by 15 · see citing works

Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.

Bona, D. D., Plaia, A., Vasto, S., Cavallone, L., Lescai, F., Franceschi, C., Licastro, F., Colonna‐Romano, G., Lio, D., Candore, G., et al. (2008) · PubMed · doi:10.1016/j.brainresrev.2008.07.003 · Cited by 13 · see citing works

Upregulation of phosphorylated αB-crystallin in the brain of children and young adults with Down syndrome

Palminiello, S., Jarząbek, K., Kaur, K., Walus, M., Rabe, A., Albertini, G., Golabek, A. A., & Kida, E. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.058 · Cited by 13 · see citing works

Secretory form of β-amyloid precursor protein is much abundantly contained in the cerebral white matter in human brain

Tokuda, T., Tanaka, K., Kametani, F., Ikeda, S., & Yanagisawa, N. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91071-5 · Cited by 9 · see citing works

P4.57 STIFFNESS OF THE LARGE ARTERIES IN INDIVIDUALS WITH AND WITHOUT DOWN SYNDROME

Rodrigues, A. N., Coelho, L. O., Gonçalves, W. L. S., Vasconcellos, M., Cunha, R. S., Gouvêa, S. A., & Abreu, G. (2012) · Artery Research · doi:10.1016/j.artres.2012.09.204 · Cited by 9 · see citing works

Plasma amyloid β protein 1-42 levels in fetuses with Down syndrome

Bartha, J. L., & SOOTHILL, P. W. (2004) · Early Human Development · doi:10.1016/j.earlhumdev.2004.09.003 · Cited by 8 · see citing works

Untitled work

(2000) · doi:10.1002/1531-8249(200011)48:5

Diagnosis and Management of Dementia: Review

Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) · JAMA · doi:10.1001/jama.2019.4782 · Cited by 1,451 · see citing works

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Wang, C., & Holtzman, D. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 589 · see citing works

Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students

Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386 · see citing works

Telomere Biology and Human Phenotype

Turner, K. J., Vasu, V., & Griffin, D. K. (2019) · Cells · doi:10.3390/cells8010073 · Cited by 391 · see citing works

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 291 · see citing works

Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease

Marzia Perluigi, A., Domenico, F. D., & Butterfield, D. A. (2023) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 306 · see citing works

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266 · see citing works

Rodent models in Down syndrome research: impact and future opportunities

Hérault, Y., Delabar, J. M., Fisher, E., Tybulewicz, V. L. J., Yu, E. Y., & Brault, V. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029728 · Cited by 191 · see citing works

Mouse models of Down syndrome: gene content and consequences

Gupta, M., Dhanasekaran, A. R., & Gardiner, K. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9661-8 · Cited by 167 · see citing works

Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum?

Cuello, A. C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.005 · Cited by 164 · see citing works

Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer’s Disease

Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167 · see citing works

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?

Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145 · see citing works

Dyrk1 inhibition improves Alzheimer's disease‐like pathology

Branca, C., Shaw, D. M., Belfiore, R., Gokhale, V. M., Shaw, A. Y., Foley, C., Smith, B. E., Hulme, C., Dunckley, T. L., Meechoovet, B., et al. (2017) · Aging Cell · doi:10.1111/acel.12648 · Cited by 132 · see citing works

Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline

Cole, J. H., Annus, T., Wilson, L. R., Remtulla, R., Hong, Y. T., Fryer, T. D., Acosta‐Cabronero, J., Cárdenas‐Blanco, A., Smith, R. V., Menon, D. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.006 · Cited by 128 · see citing works

APOE-amyloid interaction: Therapeutic targets

Wısnıewskı, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 125 · see citing works

Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?

Piirainen, S., Youssef, A. M., Song, C., Kalueff, A. V., Landreth, G. E., Malm, T., & Tian, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.046 · Cited by 125 · see citing works

Gardner and Sutherland's Chromosome Abnormalities and Genetic Counseling

Gardner, R. J. M., & Amor, D. J. (2018) · doi:10.1093/med/9780199329007.001.0001 · Cited by 118 · see citing works

Neurologic complications of Down syndrome: a systematic review

Santoro, J. D., Pagarkar, D., Chu, D. T., Rosso, M., Paulsen, K. C., Levitt, P. R., & Rafii, M. S. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10179-w · Cited by 106 · see citing works

Cerebrovascular pathology in Down syndrome and Alzheimer disease

Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105 · see citing works

A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer’s Disease

Provensi, G., Carta, F., Nocentini, A., Supuran, C. T., Casamenti, F., Passani, M. B., & Fossati, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194724 · Cited by 104 · see citing works

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Tramutola, A., Lanzillotta, C., Barone, E., Arena, A., Zuliani, I., Mosca, L., Blarzino, C., Butterfield, D. A., Marzia Perluigi, A., & Domenico, F. D. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0133-9 · Cited by 101 · see citing works

Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions

Dierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 101 · see citing works

Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects

Gomes, F. D. C., Mattos, M. F., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2021) · Neurology India · doi:10.4103/0028-3886.310062 · Cited by 102 · see citing works

Opportunities, barriers, and recommendations in Down syndrome research

Hendrix, J. A., Amon, A., Abbeduto, L., Agiovlasitis, S., Alsaied, T., Anderson, H. A., Bain, L. J., Baumer, N., Bhattacharyya, A., Bogunovic, D., et al. (2021) · Translational Science of Rare Diseases · doi:10.3233/trd-200090 · Cited by 100 · see citing works

Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease

Young‐Pearse, T. L., Lee, H., Hsieh, Y., Chou, V., & Selkoe, D. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.005 · Cited by 99 · see citing works

Mitochondria as pharmacological targets in Down syndrome

Valenti, D., Braidy, N., Rasmo, D. D., Signorile, A., Rossi, L., Atanasov, A. G., Volpicella, M., Henrion‐Caude, A., Nabavi, S. M., & Vacca, R. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.014 · Cited by 96 · see citing works

Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease

Velázquez, R., Tran, A., Ishimwe, E., Denner, L. A., Dave, N., Oddo, S., & Dineley, K. T. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.003 · Cited by 90 · see citing works

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease

Carmona‐Iragui, M., Balasa, M., Benejam, B., Alcolea, D. A., Fernández, S., Videla, L., Sala, I., Sánchez‐Saudinós, M. B., Morenas‐Rodríguez, E., Nogué, R. R., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.03.007 · Cited by 88 · see citing works

Down syndrome: Neurobiological alterations and therapeutic targets

Vacca, R. A., Bawari, S., Valenti, D., Tewari, D., Nabavi, S. F., Shirooie, S., Sah, A. N., Volpicella, M., Braidy, N., & Nabavi, S. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.001 · Cited by 90 · see citing works

Could Alzheimer’s Disease Originate in the Periphery and If So How So?

Morris, G., Berk, M., Maes, M. H. J., & Puri, B. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1092-y · Cited by 83 · see citing works

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 78 · see citing works

New approaches to studying early brain development in Down syndrome

Baburamani, A. A., Patkee, P. A., Arichi, T., & Rutherford, M. A. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14260 · Cited by 74 · see citing works

Editorial (Thematic Issue: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective)

Salehi, A., Ashford, J. W., & Mufson, E. J. (2015) · Current Alzheimer Research · doi:10.2174/1567205012999151021102914 · Cited by 72 · see citing works

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study

Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E. W., Christian, B. T., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00139-3 · Cited by 70 · see citing works

Aging with Down Syndrome—Where Are We Now and Where Are We Going?

Alldred, M. J., Martini, A. C., Patterson, D., Hendrix, J. A., & Granholm, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204687 · Cited by 70 · see citing works

Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome

Domenico, F. D., Tramutola, A., Barone, E., Lanzillotta, C., Defever, O., Arena, A., Zuliani, I., Foppoli, C., Iavarone, F., Vincenzoni, F., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101162 · Cited by 69 · see citing works

Prion-like mechanisms in Alzheimer disease

Walker, L. C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00016-7 · Cited by 65 · see citing works

Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome

Martini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66 · see citing works

Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis

Carmona‐Iragui, M., Videla, L., Lleó, A., & Fortea, J. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22709 · Cited by 64 · see citing works

Brain Somatic Mutation in Aging and Alzheimer's Disease

Miller, M. B., Reed, H., & Walsh, C. A. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-121520-081242 · Cited by 56 · see citing works

Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer’s Disease and in Down Syndrome Dementia

Raha‐Chowdhury, R., Henderson, J. W., Raha, A. A., Vuono, R., Bickerton, A., Jones, E. A., Fincham, R., Allinson, K. S. J., Holland, A. J., & Zaman, S. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181179 · Cited by 56 · see citing works

Perspectives on Oxidative Stress in Alzheimer’s Disease and Predictions of Future Research Emphases

Butterfield, D. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179912 · Cited by 57 · see citing works

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice

Souchet, B., Audrain, M., Billard, J. M., Dairou, J., Fol, R. R., Orefice, N. S., Tada, S., Gu, Y., Dufayet‐Chaffaud, G., Limanton, E., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0678-6 · Cited by 55 · see citing works

Impact of increased <i>APP</i> gene dose in Down syndrome and the Dp16 mouse model

Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12463 · Cited by 54 · see citing works

Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism

Barone, E., Arena, A., Head, E., Butterfield, D. A., & Marzia Perluigi, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.009 · Cited by 53 · see citing works

A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging

Baroncelli, L., Molinaro, A., Cacciante, F., Alessandri, M., Napoli, D., Putignano, E., Tola, J., Leuzzi, V., Cioni, G., & Pizzorusso, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw252 · Cited by 51 · see citing works

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease

Lee, N., Yang, S., Chieh, J.-J., Huang, P.-T., Chang, L.-M., Chiu, Y., Huang, A.-C., Chien, Y., Hwu, W., & Chiu, M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00316 · Cited by 50 · see citing works

Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology

Tramutola, A., Di Domenico, F., Barone, E., Arena, A., Giorgi, A., di Francesco, L., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., et al. (2017) · Antioxidants &amp; Redox Signaling · doi:10.1089/ars.2016.6686 · Cited by 49 · see citing works

Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia

Perez, S. E., Miguel, J. C., He, B., Malek‐Ahmadi, M. H., Abrahamson, E. E., Ikonomović, M. D., Lott, I. T., Doran, E. W., Alldred, M. J., Ginsberg, S. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01965-6 · Cited by 47 · see citing works

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome

Kleschevnikov, A. M., Yu, J., Kim, J., Lysenko, L. V., Zeng, Z., Yu, Y. E., & Mobley, W. C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.009 · Cited by 46 · see citing works

Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer’s Disease

Helman, A. M., Siever, M., McCarty, K. L., Lott, I. T., Doran, E. W., Abner, E. L., Schmitt, F. A., & Head, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180589 · Cited by 49 · see citing works

A longitudinal study of brain anatomy changes preceding dementia in Down syndrome

Pujol, J., Fenoll, R., Ribas‐Vidal, N., Martínez‐Vilavella, G., Blanco‐Hinojo, L., García‐Alba, J., Deus, J., Novell, R., & Esteba‐Castillo, S. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.024 · Cited by 47 · see citing works

Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model

Valenti, D., Rossi, L., Marzulli, D., Bellomo, F., Rasmo, D. D., Signorile, A., & Vacca, R. A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.014 · Cited by 46 · see citing works

Down syndrome, beta-amyloid and neuroimaging

Head, E., Helman, A. M., Powell, D. K., & Schmitt, F. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.013 · Cited by 45 · see citing works

The role of histidines in amyloid β fibril assembly

Brännström, K., Islam, T., Sandblad, L., & Olofsson, A. (2017) · FEBS Letters · doi:10.1002/1873-3468.12616 · Cited by 46 · see citing works

Neuropathological correlates of amyloid PET imaging in Down syndrome

Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomović, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 45 · see citing works

Recent developments with tau-based drug discovery

Iqbal, K., Liu, F., & Gong, C. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1445084 · Cited by 44 · see citing works

Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention

Lanzillotta, C., Zuliani, I., Tramutola, A., Barone, E., Blarzino, C., Folgiero, V., Caforio, M., Valentini, D., Villani, A., Locatelli, F., et al. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101892 · Cited by 44 · see citing works

Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease

Martinez, J. L., Zammit, M. D., West, N. R., Christian, B. T., & Bhattacharyya, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.703876 · Cited by 45 · see citing works

From Basic Visual Science to Neurodevelopmental Disorders: The Voyage of Environmental Enrichment-Like Stimulation

Consorti, A., Sansevero, G., Torelli, C., Berardi, N., & Sale, A. (2019) · Neural Plasticity · doi:10.1155/2019/5653180 · Cited by 43 · see citing works

The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia

Marzia Perluigi, A., Tramutola, A., Pagnotta, S. E., Barone, E., & Butterfield, D. A. (2020) · Antioxidants · doi:10.3390/antiox9090779 · Cited by 43 · see citing works

The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models

Karanfilian, L., Tosto, M. G., & Malki, K. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.004 · Cited by 40 · see citing works

Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?

Ahmed, M. M., Johnson, N. R., Boyd, T. D., Coughlan, C. M., Chial, H. J., & Potter, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718426 · Cited by 41 · see citing works

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease

Rujeedawa, T., Félez, E. C., Clare, I. C. H., Fortea, J., Strydom, A., Rebillat, A., Coppus, A. M. W., Levin, J., & Zaman, S. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194582 · Cited by 40 · see citing works

The Alteration of Chloride Homeostasis/GABAergic Signaling in Brain Disorders: Could Oxidative Stress Play a Role?

Abruzzo, P. M., Panisi, C., & Marini, M. (2021) · Antioxidants · doi:10.3390/antiox10081316 · Cited by 39 · see citing works

Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases

Zhang, M., Wang, W., Ye, Q., Fu, Y., Li, X., Yang, K., Gao, F., Zhou, A., Wei, Y., Tian, S., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01384-0 · Cited by 41 · see citing works

Modeling Down syndrome in animals from the early stage to the 4.0 models and next

Moreno, M. D. M. M., Brault, V., Birling, M., Pavlovic, G., & Hérault, Y. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2019.08.001 · Cited by 32 · see citing works

Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology

Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 44 · see citing works

Ultrastructural and dynamic studies of the endosomal compartment in Down syndrome

Botté, A., Lainé, J., Xicota, L., Heiligenstein, X., Fontaine, G., Kasri, A., Rivals, I., Goh, P. A., Faklaris, O., Cossec, J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00956-z · Cited by 37 · see citing works

Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules

Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 35 · see citing works

Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35 · see citing works

Astrocytes in Down Syndrome Across the Lifespan

Ponroy Bally, B., & Murai, K. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.702685 · Cited by 35 · see citing works

Accelerated aging and aging process in the brain

Исаев, Н. К., Генрихс, Е. Е., Оборина, М. В., & Stelmashook, E. V. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0051 · Cited by 35 · see citing works

RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome

Hamlett, E. D., Hjorth, E., Ledreux, A., Gilmore, A., Schultzberg, M., & Granholm, A. C. (2020) · Glia · doi:10.1002/glia.23779 · Cited by 34 · see citing works

Neurofibrillary Tangles of Aβx-40 in Alzheimer’s Disease Brains

Lacosta, A.-M., Insua, D., Badi, H., Pesini, P., & Sarasa, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170163 · Cited by 35 · see citing works

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Johannesson, M., Sahlin, C., Söderberg, L., Basun, H., Fälting, J. M., Möller, C., Zachrisson, O., Sunnemark, D., Svensson, A., Odergren, T., et al. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103641 · Cited by 32 · see citing works

Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline

Tudorascu, D., Laymon, C. M., Zammit, M. D., Minhas, D. S., Anderson, S., Ellison, P. A., Zaman, S. H., Ances, B. M., Sabbagh, M. N., Johnson, S., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12096 · Cited by 30 · see citing works

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes

Choi, M., Kim, A., Ham, Y., Lee, J., Kim, D., Yang, A., Jo, M. J., Yoon, E., Heo, J., Han, S., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153695 · Cited by 31 · see citing works

Mouse-based genetic modeling and analysis of Down syndrome

Xing, Z., Li, Y., Pao, A., Bennett, A. S., Tycko, B., Mobley, W. C., & Yu, Y. E. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw040 · Cited by 30 · see citing works

Role of the cystathionine β-synthase / H2S pathway in the development of cellular metabolic dysfunction and pseudohypoxia in down syndrome

Panagaki, T., Pecze, L., Randi, E. B., Nieminen, A. I., & Szabó, C. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102416 · Cited by 30 · see citing works

Aging With Down Syndrome: The Dual Diagnosis: Alzheimer’s Disease and Down Syndrome

Cipriani, G., Danti, S., Carlesi, C., & Fiorino, M. D. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317518761093 · Cited by 30 · see citing works

Transthyretin Interferes with Aβ Amyloid Formation by Redirecting Oligomeric Nuclei into Non-Amyloid Aggregates

Nilsson, L., Pamrén, A., Islam, T., Brännström, K., Surano, S., Pettersson, N., Iakovleva, I., Sandblad, L., Gharibyan, A. L., & Olofsson, A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.005 · Cited by 30 · see citing works

Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model

Mandler, M., Rockenstein, E. M., Overk, C., Mante, M., Florio, J. B., Adame, A., Kim, C., Santic, R., Schneeberger, A., Mattner, F., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.002 · Cited by 29 · see citing works

Alzheimer's disease amyloid-β pathology in the lens of the eye

Moncaster, J. A., Moir, R. D., Burton, M. A., Chadwick, O., Minaeva, O. V., Alvarez, V. E., Ericsson, M., Clark, J. I., McKee, A. C., Tanzi, R. E., et al. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108974 · Cited by 30 · see citing works

Is It the Twilight of BACE1 Inhibitors?

Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28 · see citing works

The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome

Zuliani, I., Lanzillotta, C., Tramutola, A., Francioso, A., Pagnotta, S. E., Barone, E., Marzia Perluigi, A., & Domenico, F. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00978-4 · Cited by 29 · see citing works

Amnestic and non‐amnestic symptoms of dementia: An international study of Alzheimer's disease in people with Down's syndrome

Fonseca, L. M., Padilla, C., Jones, E., Neale, N., Haddad, G. G., Mattar, G. P., Barros, E., Clare, I. C. H., Busatto, G. F., Bottino, C. M. C., et al. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5283 · Cited by 27 · see citing works

Mental Health Status of Psychogeriatric Patients During the 2019 New Coronavirus Disease (COVID-19) Pandemic and Effects on Caregiver Burden

Penteado, C. T., Loureiro, J. C., Pais, M. V., Carvalho, C. L., Sant’Ana, L. C. F. G., Valiengo, L. D. C. L., Stella, F., & Forlenza, O. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.578672 · Cited by 27 · see citing works

The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice

Ahmed, M. M., Wang, A. C., Elos, M. T., Chial, H. J., Sillau, S., Solano, D. A., Coughlan, C. M., Aghili, L., Anton, P. E., Markham, N. E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105694 · Cited by 30 · see citing works

Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models

Lanzillotta, C., Tramutola, A., Meier, S. E., Schmitt, F. A., Barone, E., Marzia Perluigi, A., Domenico, F. D., & Abisambra, J. F. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170617 · Cited by 25 · see citing works

Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models

Tosh, J. L., Rhymes, E. R., Mumford, P., Whittaker, H. T., Pulford, L. J., Noy, S. J., Cleverley, K., LonDownS Consortium, Strydom, A., Fisher, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85062-3 · Cited by 26 · see citing works

Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer’s Disease

Barbosa, F. A. R., Canto, R. F. S., Teixeira, K. F., de Souza, A. S., de Oliveira, A. S., & Braga, A. L. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220224161454 · Cited by 26 · see citing works

Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan

LeVine, H., Spielmann, H. P., Matveev, S., Cauvi, F. M., Murphy, M. P., Beckett, T. L., McCarty, K. L., Lott, I. T., Doran, E. W., Schmitt, F. A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.005 · Cited by 26 · see citing works

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue

Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Šimić, G., Doran, E. W., Lott, I. T., Carroll, S. L., Bharani, K., Thomas, S., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00414-3 · Cited by 26 · see citing works

The Properties of Amyloid-β Fibrils Are Determined by their Path of Formation

Brännström, K., Islam, T., Gharibyan, A. L., Iakovleva, I., Nilsson, L., Lee, C. C., Sandblad, L., Pamrén, A., & Olofsson, A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.001 · Cited by 25 · see citing works

Relationship between single nucleotide polymorphisms in the 3′UTR of amyloid precursor protein and risk of Alzheimer’s disease and its mechanism

Zhou, Q., Luo, L., Wang, X., & Li, X. (2019) · Bioscience Reports · doi:10.1042/bsr20182485 · Cited by 25 · see citing works

Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease

Garcı́a, O., & Aguilar, L. F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.987212 · Cited by 25 · see citing works

Overexpressed Down Syndrome Cell Adhesion Molecule (DSCAM) Deregulates P21-Activated Kinase (PAK) Activity in an In Vitro Neuronal Model of Down Syndrome: Consequences on Cell Process Formation and Extension

Pérez-Núñez, R., Barraza, N., González‐Jamett, A. M., Cárdenas, A. M., Barnier, J., & Caviedes, P. A. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9613-9 · Cited by 25 · see citing works

Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models

Kumar, S., Lemere, C. A., & Walter, J. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00959-w · Cited by 24 · see citing works

Brain Aging and Alzheimer’s Disease in Down Syndrome

Helman, A. M., Pelt, K. L. V., Schmitt, F. A., & Head, E. (2022) · doi:10.1093/oxfordhb/9780190645441.013.22 · Cited by 1 · see citing works

Down syndrome and Alzheimer's disease: A link between development and aging

Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 157 · see citing works

F3–01–02: Alzheimer's disease and Down syndrome

Lemere, C. A. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.223

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383 · see citing works

Down syndrome: a model for the study of Alzheimer’s disease and aging

Delabar, J. M., Blouin, J., Rahmani, Z., Créau, N., Chettouh, Z., Nicole, A., Bruel, A., de Blois, M., & Sinet, P. (1990) · New vistas in drug research · doi:10.1007/978-3-7091-9098-2_17 · Cited by 4 · see citing works